Analyst Price Targets — NEO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 11:41 am | — | Piper Sandler | $13.00 | $9.97 | TheFly | NeoGenomics price target raised to $13 from $12 at Piper Sandler |
| October 28, 2025 8:10 pm | — | Leerink Partners | $14.00 | $9.92 | TheFly | NeoGenomics price target raised to $14 from $12 at Leerink |
| September 2, 2025 11:10 am | — | Stephens | $11.00 | $8.81 | TheFly | NeoGenomics price target raised to $11 from $6.50 at Stephens |
| August 4, 2025 10:44 am | — | Piper Sandler | $11.00 | $5.67 | TheFly | NeoGenomics price target lowered to $11 from $12 at Piper Sandler |
| July 30, 2025 12:59 pm | — | Morgan Stanley | $8.00 | $5.10 | TheFly | NeoGenomics price target lowered to $8 from $10 at Morgan Stanley |
| July 29, 2025 5:55 pm | — | Needham | $8.00 | $5.25 | StreetInsider | Neogenomics (NEO) PT Lowered to $8 at NeedhamMember Login |
| May 6, 2025 10:42 am | David Westenberg | Piper Sandler | $12.00 | $7.84 | TheFly | NeoGenomics price target lowered to $12 from $18 at Piper Sandler |
| January 11, 2025 7:45 pm | Mark Massaro | BTIG | $18.00 | $14.77 | TheFly | NeoGenomics price target lowered to $18 from $21 at BTIG |
| July 30, 2024 6:04 am | Mike Matson | Needham | $19.00 | $14.64 | StreetInsider | Needham Reiterates Buy Rating on Neogenomics (NEO) |
| May 2, 2024 5:24 am | Mark Massaro | BTIG | $21.00 | $13.96 | StreetInsider | Neogenomics (NEO) PT Lowered to $21 at BTIG |
Latest News for NEO
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the launch of RaDaR® ST, its circulating tumor DNA assay for detecting molecular residual disease.
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group Announces 47th Annual NEO: The Conference for Neonatology.
Shares of NeoGenomics, Inc. (NASDAQ: NEO - Get Free Report) have been assigned an average rating of "Hold" from the fourteen research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, seven have given a hold recommendation, five have given a buy recommendation and
NeoGenomics (NEO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the TD Cowen 46th Annual Health Care Conference in Boston and the Leerink Global Healthcare Conference in Miami.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NEO.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.